The North America AI in Biotechnology Market was valued at $1841.7 Million in 2030 and projected to reach to $4418.5 Million by 2035, representing a compound annual growth rate of 19.3%. North America's AI in biotechnology market is poised for exceptional growth, expanding from $1,841.7 million in 2030 to $4,418.5 million by 2035, representing a robust 19.3% CAGR.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America dominates the global AI in biotechnology market with commanding market share, driven by the region's concentration of leading biotech firms, pharmaceutical giants, and innovative startups leveraging AI for competitive advantage.
The region benefits from substantial government funding, venture capital influx, and corporate R&D spending, with major institutions and companies investing heavily in AI-powered drug discovery, genomics analysis, and personalized medicine initiatives.
North America's sophisticated healthcare systems, regulatory frameworks, and digital health adoption create an ideal environment for AI biotechnology deployment, enabling rapid clinical validation and market commercialization of AI-driven solutions.
The region demonstrates early and widespread adoption of artificial intelligence across drug discovery pipelines, clinical trials, and biomarker identification, positioning North America as the innovation hub for AI biotechnology applications.
| Report Metric | Details |
|---|---|
| Base Year | 2030 |
| Fastest Growing Segment | DRUG DISCOVERY (Type) |
| Forecast Period | 2030–2035 |
| Growth Rate | CAGR of 18.5% from 2030 to 2035 |
| Largest Segment | CLOUD-BASED SOLUTIONS (Deployment Mode) |
| Market Size Base Year (Billions) | ~USD 9.72 (2030) |
| Revenue Forecast (Billions) | ~USD 22.72 (2035) |
| Segments Covered | Offering, Function, Type, Deployment Mode, End User |
5 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| NVIDIA CORPORATION | United States | Public Company | Data Center AI Compute & Networking,Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro), |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Arrays and genotyping consumables, |
| RECURSION | United States | Public Company | Platform collaboration and milestones,Internal pipeline R&D funding (capitalized/other income),Other services and data partnerships, |
| SCHRöDINGER, INC. | United States | Public Company | Software,Drug Discovery – Collaborations (e.g., Novartis and others),Drug Discovery – Internal Pipeline, |
| BENEVOLENTAI | United Kingdom | Private Company | AI discovery platform and licenses,Collaborative R&D projects and services,Custom data/ontology and analytics solutions, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, sexual and reproductive health, transplant, viral load),PCR and digital PCR instruments and consumables, |
| TEMPUS | United States | Public Company | Oncology NGS diagnostics (xT, xR, solid tumor and hematologic panels),Other diagnostics (PCR profiling, pathology, inherited conditions, pharmacogenomics nP),Data licensing and software (Insights, Lens, Hub, Next, Algos, Organoids, Trials), |
| SOPHIA GENETICS | Switzerland | Public Company | SOPHiA DDM platform subscriptions and usage-based analytics,Implementation, support, and workflow services,Biopharma collaborations and data-driven research solutions, |
| PREDICTIVE ONCOLOGY | United States | Public Company | Compute Services and Treasury Management,Drug Discovery Services, |
| XTALPI INC. | China | Public Company | AI-driven drug discovery solutions (hit discovery, optimization, biology, PepiX),Computational software platforms (XFEP, XMolGen, PatSight, XtalGazer),Automation hardware and integrated workstations (XmartChem, ChemPlus), |
NVIDIA Corporation is a publicly traded technology company founded in 1993 and headquartered in the United States. With 42,000 employees, the company designs and manufactures graphics processing units and system-on-chip units. NVIDIA serves markets including gaming, professional visualization, data centers, and artificial intelligence.
Illumina, Inc. is a publicly traded genomics company founded in 1998 and based in the United States. The company employs 8,625 people and specializes in DNA sequencing and array-based technologies. Illumina's platforms are used for applications in research, clinical diagnostics, and precision medicine.
Recursion is a publicly traded biotechnology company founded in 2013 and headquartered in the United States. With 600 employees, the company uses machine learning and high-throughput biology to discover and develop therapeutics. Recursion focuses on identifying novel drug candidates through computational and experimental approaches.
Schrödinger, Inc. is a publicly traded computational chemistry and drug discovery company founded in 1990 and based in the United States. The company employs 850 people and develops software platforms for molecular simulation and drug design. Schrödinger's tools are used by pharmaceutical and biotechnology companies to accelerate drug development.
BenevolentAI is a privately held artificial intelligence company founded in 2013 and headquartered in the United Kingdom. With 173 employees, the company applies machine learning and AI to drug discovery and development. BenevolentAI focuses on identifying new therapeutic targets and repurposing existing drugs for various diseases.
QIAGEN is a publicly traded life sciences company founded in 1984 and headquartered in the Netherlands. With 5,500 employees, the company develops and manufactures sample preparation and molecular testing technologies. QIAGEN serves customers in molecular diagnostics, applied testing, and academic research.
Tempus is a publicly traded artificial intelligence and precision medicine company founded in 2015 and based in the United States. With 3,800 employees, the company leverages machine learning and data analytics to improve cancer treatment and outcomes. Tempus analyzes clinical and molecular data to provide actionable insights for oncology care.
Sophia Genetics is a publicly traded digital health company founded in 2011 and headquartered in Switzerland. With 415 employees, the company develops AI-powered platforms for genomic data interpretation and clinical decision support. Sophia Genetics serves hospitals, diagnostic laboratories, and research institutions globally.
Predictive Oncology is a publicly traded cancer diagnostics and treatment company founded in 2002 and based in the United States. With 14 employees, the company develops personalized medicine solutions for oncology patients. Predictive Oncology focuses on tumor profiling and treatment prediction technologies.
XtalPi Inc. is a publicly traded artificial intelligence and drug discovery company founded in 2015 and headquartered in China. The company uses machine learning and computational chemistry to accelerate drug discovery and development. XtalPi focuses on molecular simulation and structure-based drug design.
| Country | 2025 size (native) |
|---|---|
| US | USD 8715.3 Million |
| Canada | USD 436.6 Million |
North America's AI in biotechnology market is estimated at $1,841.7 million in 2030, representing a substantial portion of global market activity.
North America's AI in biotechnology market is forecast to reach $4,418.5 million by 2035, reflecting strong regional growth momentum.
North America's AI in biotechnology market is expected to grow at a compound annual growth rate of 19.3% from 2030 to 2035.
North America's growth is driven by advanced healthcare infrastructure, substantial pharmaceutical R&D investments, early AI adoption, and a robust ecosystem of startups and academic institutions.
North America's 19.3% CAGR exceeds the global average of 18.5%, demonstrating the region's accelerated adoption and leadership in AI-driven biotechnology innovation.
This market research study primarily relied on secondary sources, directories, and databases to collect information for this technical, market-oriented, and financial analysis of the AI in biotechnology market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from major market players, and industry consultants, among others, to gather and verify critical qualitative and quantitative data and assess market prospects. The size of the AI in biotechnology market was estimated using multiple secondary research methods and confirmed with inputs from primary research to determine the final market size.
The secondary research process involved extensively using secondary sources, including directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the World Health Organization (WHO), the Organization for Economic Co-operation and Development (OECD), Healthcare Information and Management Systems Society (HIMSS), Centers for Disease Control and Prevention (CDC), ClinicalTrials.gov, expert interviews, and MarketsandMarkets analysis.
Secondary research was conducted to gather information for the detailed, technical, market-focused, and commercial analysis of the AI in biotechnology market. It was also used to collect key information about major players, market classification, and segmentation based on industry trends, down to the most detailed level, along with significant developments related to market and technology perspectives. Additionally, a database of leading industry players was compiled using secondary research.
During the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources mainly include industry experts from core and related industries, preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations involved in all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, such as key industry participants, subject-matter experts (SMEs), C-level executives of leading market players, and industry consultants, among other specialists, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
Primary research was conducted to identify segmentation types, industry trends, key players, and key market dynamics such as drivers, restraints, opportunities, challenges, and strategies adopted by key players.
After completing the market engineering process- which includes calculations for market statistics, market breakdown, size estimations, forecasting, and data triangulation- extensive primary research was carried out. This research aimed to gather information and verify the key numbers obtained during the market analysis. Additionally, primary research was used to identify different types of market segmentation, analyze industry trends, evaluate the competitive landscape of AI solutions for biotechnology offered by various players, and understand key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies employed by key market players.
In the complete market engineering process, the top-down and bottom-up approaches, along with several data triangulation methods, were extensively used to estimate and forecast the market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was conducted on the entire market engineering process to identify key information and insights throughout the report.
Breakdown of Primary Interviews
Note 1: Others include sales, marketing, and product managers.
Note 2: Tiers are defined based on a company’s total revenue, as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
The market size estimates and forecasts in this study are based on a combination of the bottom-up approach (revenue share analysis of leading players) and the top-down approach (evaluation of utilization, adoption, and penetration trends by offering, function, deployment mode, end user, and region).

After determining the overall market size from the estimation process described above, the market for AI in biotechnology was divided into various segments and subsegments. To finalize the overall market analysis and obtain accurate statistics for all segments and subsegments, data triangulation and market breakdown techniques were used whenever applicable. The data was cross-verified by examining different factors and trends from both the demand and supply sides of the market for AI in biotechnology.
The AI in biotechnology market includes technologies that use artificial intelligence to advance drug discovery, genomics, and personalized medicine. This market is defined by the growing utilization of machine learning and data analytics to improve research and development efficiency.
Full forecast, segment splits, and company analysis for all AI in Biotechnology Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report